Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

178.39USD
19 Jul 2019
Change (% chg)

$-1.15 (-0.64%)
Prev Close
$179.54
Open
$180.67
Day's High
$181.54
Day's Low
$178.20
Volume
1,195,370
Avg. Vol
1,139,109
52-wk High
$210.18
52-wk Low
$166.30

Latest Key Developments (Source: Significant Developments)

Nuevolution Says Board Has Resolved To Apply For Delisting From Nasdaq Stockholm
Thursday, 11 Jul 2019 

July 11 (Reuters) - Nuevolution AB (publ) ::NUEVOLUTION APPLIES FOR DELISTING.AT REQUEST OF AMGEN, BOARD HAS RESOLVED TO APPLY FOR DELISTING OF NUEVOLUTION'S SHARES FROM NASDAQ STOCKHOLM.  Full Article

Amgen Comments On Pcsk9 Patent Litigation In Germany
Thursday, 11 Jul 2019 

July 11 (Reuters) - Amgen Inc ::AMGEN INC. - AMGEN COMMENTS ON PCSK9 PATENT LITIGATION IN GERMANY.AMGEN SAYS "PLANS TO ENFORCE THE COURT’S DECISION AGAINST PRALUENT IN GERMANY".AMGEN - DÜSSELDORF REGIONAL COURT RULED IN FAVOR OF AMGEN CONFIRMING THAT SANOFI-AVENTIS’ PRALUENT® (ALIROCUMAB) INFRINGES AN AMGEN PATENT.AMGEN INC - AT THIS TIME NOT SEEKING REMOVAL OF EXISTING PRALUENT SUPPLIES AVAILABLE AT HOSPITALS AND PHARMACIES.  Full Article

Amgen Wins FDA Approval For Kanjinti Injection For Treatment Of Breast Cancer, Gastroesophageal Junction Adenocarcinoma - FDA
Thursday, 13 Jun 2019 

June 13 (Reuters) - U.S. FDA::AMGEN WINS FDA APPROVAL FOR KANJINTI INJECTION FOR TREATMENT OF BREAST CANCER, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - FDA WEBSITE.U.S. FDA SAYS KANJINTI (TRASTUZUMAB-ANNS) IS BIOSIMILAR TO HERCEPTIN (TRASTUZUMAB).U.S. FDA SAYS KANJINTI COMES WITH A BOXED WARNING FOR CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, PULMONARY TOXICITY.  Full Article

Amgen Announces Public Cash Offer To Shareholders Of Nuevolution
Wednesday, 22 May 2019 

May 22 (Reuters) - Amgen::AMGEN ANNOUNCES A RECOMMENDED PUBLIC CASH OFFER TO THE SHAREHOLDERS OF NUEVOLUTION.AMGEN INC SAYS AMGEN OFFERS SEK 32.50 IN CASH FOR EACH SHARE IN NUEVOLUTION.AMGEN INC SAYS TOTAL VALUE OF OFFER AMOUNTS TO APPROXIMATELY SEK 1,610 MILLION, WHICH CORRESPONDS TO APPROXIMATELY USD 167 MILLION.AMGEN INC SAYS OFFER IS NOT SUBJECT TO ANY FINANCING CONDITION. OFFER IS FULLY FINANCED BY CASH ON HAND..AMGEN INC SAYS AMGEN DOES NOT INTEND TO CHANGE COMPOSITION OF NUEVOLUTION'S MANAGEMENT TEAM AND KEY EMPLOYEES FOLLOWING IMPLEMENTATION OF OFFER.  Full Article

Amgen Qtrly GAAP EPS $3.18
Wednesday, 1 May 2019 

April 30 (Reuters) - Amgen Inc ::AMGEN QTRLY GAAP EARNINGS PER SHARE $3.18; QTRLY NON-GAAP EARNINGS PER SHARE $3.56.AMGEN QTRLY TOTAL REVENUES $5,557 MILLION VERSUS $5,554 MILLION.Q1 EARNINGS PER SHARE VIEW $3.48, REVENUE VIEW $5.54 BILLION -- REFINITIV IBES DATA.AMGEN - QTRLY PRODUCT SALES DECLINED 1 PERCENT GLOBALLY.AMGEN SEES 2019 TOTAL REVENUE $22.0 BILLION TO $22.9 BILLION.AMGEN SEES 2019 GAAP EARNINGS PER SHARE $11.68 TO $12.73; SEES 2019 NON-GAAP EARNINGS PER SHARE $13.25 TO $14.30.FY2019 EARNINGS PER SHARE VIEW $14.10, REVENUE VIEW $22.78 BILLION -- REFINITIV IBES DATA.  Full Article

U.S. FDA Says Granted Approval Of Evenity To Amgen
Wednesday, 10 Apr 2019 

April 9 (Reuters) - U.S. Food and Drug Administration::U.S. FDA- GRANTED APPROVAL OF EVENITY TO AMGEN.U.S. FDA - EVENITY COMES WITH A BOXED WARNING.  Full Article

Amgen Says CEO's Total Compensation For FY 2018 Was $18.6 Mln vs $16.9 Mln In FY 2017
Tuesday, 9 Apr 2019 

April 8 (Reuters) - Amgen Inc ::AMGEN SAYS CEO ROBERT A. BRADWAY'S TOTAL COMPENSATION FOR FY 2018 WAS $18.6 MILLION VERSUS $16.9 MILLION IN FY 2017- SEC FILING.AMGEN SAYS CEO ROBERT A. BRADWAY'S TOTAL COMPENSATION FOR FY 2018 INCLUDES $8.7 MILLION STOCK AWARDS.AMGEN SAYS RATIO OF 2018 ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES IS 141 TO 1.  Full Article

Regeneron And Sanofi Disagree With Verdict Upholding 3 Of 5 Amgen U.S. Patent Claims Relating To PCSK9 Antibodies
Tuesday, 26 Feb 2019 

Feb 25 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON AND SANOFI STRONGLY DISAGREE WITH VERDICT UPHOLDING THREE OF FIVE AMGEN U.S. PATENT CLAIMS RELATING TO PCSK9 ANTIBODIES.REGENERON PHARMACEUTICALS INC - CONTINUE TO BELIEVE IN DIFFERENTIATED CLINICAL PROFILE OF PRALUENT.REGENERON - CO, SANOFI TO FILE POST-TRIAL MOTIONS WITH DISTRICT COURT OVER NEXT FEW MONTHS, SEEKING TO OVERTURN JURY VERDICT & REQUESTING NEW TRIAL.REGENERON PHARMACEUTICALS INC - IF NECESSARY SANOFI, CO PLAN TO APPEAL TO U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT.REGENERON PHARMACEUTICALS INC - VERDICT DOES NOT IMPACT U.S. PHYSICIANS' AND PATIENTS' ACCESS TO PRALUENT.  Full Article

Jury Upholds Amgen's Patents On Repatha (Evolocumab)
Tuesday, 26 Feb 2019 

Feb 25 (Reuters) - Amgen Inc ::JURY UPHOLDS AMGEN'S PATENTS ON REPATHA® (EVOLOCUMAB).AMGEN INC - JURY DELIVERED A VERDICT IN AMGEN'S FAVOR UPHOLDING VALIDITY OF TWO AMGEN PATENTS RELATED TO PCSK9 ANTIBODIES.AMGEN INC - JURY FOUND THAT AMGEN PATENTS MEET LEGAL REQUIREMENTS OF WRITTEN DESCRIPTION AND ENABLEMENT.AMGEN INC - AMGEN IS SEEKING TO ENFORCE PCSK9 ANTIBODY PATENTS PATENTS IN NATIONAL COURTS IN EUROPE AND JAPAN AGAINST SANOFI AND REGENERON.  Full Article

Abilita Bio And Amgen Enter Into A Multi-Target Collaboration
Wednesday, 13 Feb 2019 

Feb 13 (Reuters) - ABILITA BIO ::ABILITA BIO AND AMGEN ENTER INTO A MULTI-TARGET COLLABORATION.ABILITA BIO - FINANCIAL DETAILS WERE NOT DISCLOSED.ABILITA BIO - CO TO LEVERAGE MEMBRANE PROTEIN TECHNOLOGY PLATFORM TO SUPPORT AMGEN'S RESEARCH AND DEVELOPMENT EFFORTS ON INTEGRAL MEMBRANE PROTEIN TARGETS.  Full Article

Photo

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.